Global Neurodegenerative Drugs Market Research Report 2025(Status and Outlook)
Neurodegenerative drugs are medications used to manage and alleviate symptoms associated with neurodegenerative diseases. They may target various aspects of disease progression, such as cognitive function, motor symptoms, and inflammation.
The global Neurodegenerative Drugs market size was estimated at USD 115030.0 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 0.06% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Neurodegenerative Drugs market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Neurodegenerative Drugs market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neurodegenerative Drugs market.
Global Neurodegenerative Drugs Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Market Segmentation (by Type)
NMDA
SSRIs
Dopamine Inhibitors
Market Segmentation (by Application)
Parkinson?s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer?s Disease
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurodegenerative Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neurodegenerative Drugs, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Neurodegenerative Drugs market size was estimated at USD 115030.0 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 0.06% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Neurodegenerative Drugs market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Neurodegenerative Drugs market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neurodegenerative Drugs market.
Global Neurodegenerative Drugs Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Market Segmentation (by Type)
NMDA
SSRIs
Dopamine Inhibitors
Market Segmentation (by Application)
Parkinson?s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer?s Disease
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Neurodegenerative Drugs Market
- Overview of the regional outlook of the Neurodegenerative Drugs Market:
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurodegenerative Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neurodegenerative Drugs, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Neurodegenerative Drugs
1.2 Key Market Segments
1.2.1 Neurodegenerative Drugs Segment by Type
1.2.2 Neurodegenerative Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEURODEGENERATIVE DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neurodegenerative Drugs Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Neurodegenerative Drugs Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEURODEGENERATIVE DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Neurodegenerative Drugs Product Life Cycle
3.3 Global Neurodegenerative Drugs Sales by Manufacturers (2020-2025)
3.4 Global Neurodegenerative Drugs Revenue Market Share by Manufacturers (2020-2025)
3.5 Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Neurodegenerative Drugs Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Neurodegenerative Drugs Market Competitive Situation and Trends
3.8.1 Neurodegenerative Drugs Market Concentration Rate
3.8.2 Global 5 and 10 Largest Neurodegenerative Drugs Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 NEURODEGENERATIVE DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Neurodegenerative Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEURODEGENERATIVE DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neurodegenerative Drugs Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Neurodegenerative Drugs Market
5.7 ESG Ratings of Leading Companies
6 NEURODEGENERATIVE DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
6.3 Global Neurodegenerative Drugs Market Size Market Share by Type (2020-2025)
6.4 Global Neurodegenerative Drugs Price by Type (2020-2025)
7 NEURODEGENERATIVE DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurodegenerative Drugs Market Sales by Application (2020-2025)
7.3 Global Neurodegenerative Drugs Market Size (M USD) by Application (2020-2025)
7.4 Global Neurodegenerative Drugs Sales Growth Rate by Application (2020-2025)
8 NEURODEGENERATIVE DRUGS MARKET SALES BY REGION
8.1 Global Neurodegenerative Drugs Sales by Region
8.1.1 Global Neurodegenerative Drugs Sales by Region
8.1.2 Global Neurodegenerative Drugs Sales Market Share by Region
8.2 Global Neurodegenerative Drugs Market Size by Region
8.2.1 Global Neurodegenerative Drugs Market Size by Region
8.2.2 Global Neurodegenerative Drugs Market Size Market Share by Region
8.3 North America
8.3.1 North America Neurodegenerative Drugs Sales by Country
8.3.2 North America Neurodegenerative Drugs Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Neurodegenerative Drugs Sales by Country
8.4.2 Europe Neurodegenerative Drugs Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Neurodegenerative Drugs Sales by Region
8.5.2 Asia Pacific Neurodegenerative Drugs Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Neurodegenerative Drugs Sales by Country
8.6.2 South America Neurodegenerative Drugs Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Neurodegenerative Drugs Sales by Region
8.7.2 Middle East and Africa Neurodegenerative Drugs Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 NEURODEGENERATIVE DRUGS MARKET PRODUCTION BY REGION
9.1 Global Production of Neurodegenerative Drugs by Region(2020-2025)
9.2 Global Neurodegenerative Drugs Revenue Market Share by Region (2020-2025)
9.3 Global Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Neurodegenerative Drugs Production
9.4.1 North America Neurodegenerative Drugs Production Growth Rate (2020-2025)
9.4.2 North America Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Neurodegenerative Drugs Production
9.5.1 Europe Neurodegenerative Drugs Production Growth Rate (2020-2025)
9.5.2 Europe Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Neurodegenerative Drugs Production (2020-2025)
9.6.1 Japan Neurodegenerative Drugs Production Growth Rate (2020-2025)
9.6.2 Japan Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Neurodegenerative Drugs Production (2020-2025)
9.7.1 China Neurodegenerative Drugs Production Growth Rate (2020-2025)
9.7.2 China Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Novartis
10.1.1 Novartis Basic Information
10.1.2 Novartis Neurodegenerative Drugs Product Overview
10.1.3 Novartis Neurodegenerative Drugs Product Market Performance
10.1.4 Novartis Business Overview
10.1.5 Novartis SWOT Analysis
10.1.6 Novartis Recent Developments
10.2 Pfizer
10.2.1 Pfizer Basic Information
10.2.2 Pfizer Neurodegenerative Drugs Product Overview
10.2.3 Pfizer Neurodegenerative Drugs Product Market Performance
10.2.4 Pfizer Business Overview
10.2.5 Pfizer SWOT Analysis
10.2.6 Pfizer Recent Developments
10.3 Merck Serono
10.3.1 Merck Serono Basic Information
10.3.2 Merck Serono Neurodegenerative Drugs Product Overview
10.3.3 Merck Serono Neurodegenerative Drugs Product Market Performance
10.3.4 Merck Serono Business Overview
10.3.5 Merck Serono SWOT Analysis
10.3.6 Merck Serono Recent Developments
10.4 Biogen Idec
10.4.1 Biogen Idec Basic Information
10.4.2 Biogen Idec Neurodegenerative Drugs Product Overview
10.4.3 Biogen Idec Neurodegenerative Drugs Product Market Performance
10.4.4 Biogen Idec Business Overview
10.4.5 Biogen Idec Recent Developments
10.5 TEVA
10.5.1 TEVA Basic Information
10.5.2 TEVA Neurodegenerative Drugs Product Overview
10.5.3 TEVA Neurodegenerative Drugs Product Market Performance
10.5.4 TEVA Business Overview
10.5.5 TEVA Recent Developments
10.6 UCB
10.6.1 UCB Basic Information
10.6.2 UCB Neurodegenerative Drugs Product Overview
10.6.3 UCB Neurodegenerative Drugs Product Market Performance
10.6.4 UCB Business Overview
10.6.5 UCB Recent Developments
10.7 Boehringer Ingelheim
10.7.1 Boehringer Ingelheim Basic Information
10.7.2 Boehringer Ingelheim Neurodegenerative Drugs Product Overview
10.7.3 Boehringer Ingelheim Neurodegenerative Drugs Product Market Performance
10.7.4 Boehringer Ingelheim Business Overview
10.7.5 Boehringer Ingelheim Recent Developments
10.8 Sanofi
10.8.1 Sanofi Basic Information
10.8.2 Sanofi Neurodegenerative Drugs Product Overview
10.8.3 Sanofi Neurodegenerative Drugs Product Market Performance
10.8.4 Sanofi Business Overview
10.8.5 Sanofi Recent Developments
10.9 GlaxoSmithKline
10.9.1 GlaxoSmithKline Basic Information
10.9.2 GlaxoSmithKline Neurodegenerative Drugs Product Overview
10.9.3 GlaxoSmithKline Neurodegenerative Drugs Product Market Performance
10.9.4 GlaxoSmithKline Business Overview
10.9.5 GlaxoSmithKline Recent Developments
10.10 Livzon Pharmaceutical
10.10.1 Livzon Pharmaceutical Basic Information
10.10.2 Livzon Pharmaceutical Neurodegenerative Drugs Product Overview
10.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.10.4 Livzon Pharmaceutical Business Overview
10.10.5 Livzon Pharmaceutical Recent Developments
10.11 Haisco Pharmaceutical
10.11.1 Haisco Pharmaceutical Basic Information
10.11.2 Haisco Pharmaceutical Neurodegenerative Drugs Product Overview
10.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.11.4 Haisco Pharmaceutical Business Overview
10.11.5 Haisco Pharmaceutical Recent Developments
10.12 Jingxin Pharmaceutical
10.12.1 Jingxin Pharmaceutical Basic Information
10.12.2 Jingxin Pharmaceutical Neurodegenerative Drugs Product Overview
10.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.12.4 Jingxin Pharmaceutical Business Overview
10.12.5 Jingxin Pharmaceutical Recent Developments
10.13 Dongcheng Biochemicals
10.13.1 Dongcheng Biochemicals Basic Information
10.13.2 Dongcheng Biochemicals Neurodegenerative Drugs Product Overview
10.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Product Market Performance
10.13.4 Dongcheng Biochemicals Business Overview
10.13.5 Dongcheng Biochemicals Recent Developments
10.14 Hisun Pharmaceutical
10.14.1 Hisun Pharmaceutical Basic Information
10.14.2 Hisun Pharmaceutical Neurodegenerative Drugs Product Overview
10.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.14.4 Hisun Pharmaceutical Business Overview
10.14.5 Hisun Pharmaceutical Recent Developments
10.15 Luye Pharma
10.15.1 Luye Pharma Basic Information
10.15.2 Luye Pharma Neurodegenerative Drugs Product Overview
10.15.3 Luye Pharma Neurodegenerative Drugs Product Market Performance
10.15.4 Luye Pharma Business Overview
10.15.5 Luye Pharma Recent Developments
10.16 Ark Pharmaceutical
10.16.1 Ark Pharmaceutical Basic Information
10.16.2 Ark Pharmaceutical Neurodegenerative Drugs Product Overview
10.16.3 Ark Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.16.4 Ark Pharmaceutical Business Overview
10.16.5 Ark Pharmaceutical Recent Developments
10.17 Kanghong Pharmaceutical
10.17.1 Kanghong Pharmaceutical Basic Information
10.17.2 Kanghong Pharmaceutical Neurodegenerative Drugs Product Overview
10.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.17.4 Kanghong Pharmaceutical Business Overview
10.17.5 Kanghong Pharmaceutical Recent Developments
10.18 Huahai Pharmaceutical
10.18.1 Huahai Pharmaceutical Basic Information
10.18.2 Huahai Pharmaceutical Neurodegenerative Drugs Product Overview
10.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.18.4 Huahai Pharmaceutical Business Overview
10.18.5 Huahai Pharmaceutical Recent Developments
10.19 BORA PHARMACEUTICALS
10.19.1 BORA PHARMACEUTICALS Basic Information
10.19.2 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Overview
10.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Market Performance
10.19.4 BORA PHARMACEUTICALS Business Overview
10.19.5 BORA PHARMACEUTICALS Recent Developments
11 NEURODEGENERATIVE DRUGS MARKET FORECAST BY REGION
11.1 Global Neurodegenerative Drugs Market Size Forecast
11.2 Global Neurodegenerative Drugs Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neurodegenerative Drugs Market Size Forecast by Country
11.2.3 Asia Pacific Neurodegenerative Drugs Market Size Forecast by Region
11.2.4 South America Neurodegenerative Drugs Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Neurodegenerative Drugs by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)
12.1 Global Neurodegenerative Drugs Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Neurodegenerative Drugs by Type (2026-2033)
12.1.2 Global Neurodegenerative Drugs Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Neurodegenerative Drugs by Type (2026-2033)
12.2 Global Neurodegenerative Drugs Market Forecast by Application (2026-2033)
12.2.1 Global Neurodegenerative Drugs Sales (K MT) Forecast by Application
12.2.2 Global Neurodegenerative Drugs Market Size (M USD) Forecast by Application (2026-2033)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Neurodegenerative Drugs
1.2 Key Market Segments
1.2.1 Neurodegenerative Drugs Segment by Type
1.2.2 Neurodegenerative Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEURODEGENERATIVE DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neurodegenerative Drugs Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Neurodegenerative Drugs Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEURODEGENERATIVE DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Neurodegenerative Drugs Product Life Cycle
3.3 Global Neurodegenerative Drugs Sales by Manufacturers (2020-2025)
3.4 Global Neurodegenerative Drugs Revenue Market Share by Manufacturers (2020-2025)
3.5 Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Neurodegenerative Drugs Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Neurodegenerative Drugs Market Competitive Situation and Trends
3.8.1 Neurodegenerative Drugs Market Concentration Rate
3.8.2 Global 5 and 10 Largest Neurodegenerative Drugs Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 NEURODEGENERATIVE DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Neurodegenerative Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEURODEGENERATIVE DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neurodegenerative Drugs Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Neurodegenerative Drugs Market
5.7 ESG Ratings of Leading Companies
6 NEURODEGENERATIVE DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
6.3 Global Neurodegenerative Drugs Market Size Market Share by Type (2020-2025)
6.4 Global Neurodegenerative Drugs Price by Type (2020-2025)
7 NEURODEGENERATIVE DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurodegenerative Drugs Market Sales by Application (2020-2025)
7.3 Global Neurodegenerative Drugs Market Size (M USD) by Application (2020-2025)
7.4 Global Neurodegenerative Drugs Sales Growth Rate by Application (2020-2025)
8 NEURODEGENERATIVE DRUGS MARKET SALES BY REGION
8.1 Global Neurodegenerative Drugs Sales by Region
8.1.1 Global Neurodegenerative Drugs Sales by Region
8.1.2 Global Neurodegenerative Drugs Sales Market Share by Region
8.2 Global Neurodegenerative Drugs Market Size by Region
8.2.1 Global Neurodegenerative Drugs Market Size by Region
8.2.2 Global Neurodegenerative Drugs Market Size Market Share by Region
8.3 North America
8.3.1 North America Neurodegenerative Drugs Sales by Country
8.3.2 North America Neurodegenerative Drugs Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Neurodegenerative Drugs Sales by Country
8.4.2 Europe Neurodegenerative Drugs Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Neurodegenerative Drugs Sales by Region
8.5.2 Asia Pacific Neurodegenerative Drugs Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Neurodegenerative Drugs Sales by Country
8.6.2 South America Neurodegenerative Drugs Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Neurodegenerative Drugs Sales by Region
8.7.2 Middle East and Africa Neurodegenerative Drugs Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 NEURODEGENERATIVE DRUGS MARKET PRODUCTION BY REGION
9.1 Global Production of Neurodegenerative Drugs by Region(2020-2025)
9.2 Global Neurodegenerative Drugs Revenue Market Share by Region (2020-2025)
9.3 Global Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Neurodegenerative Drugs Production
9.4.1 North America Neurodegenerative Drugs Production Growth Rate (2020-2025)
9.4.2 North America Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Neurodegenerative Drugs Production
9.5.1 Europe Neurodegenerative Drugs Production Growth Rate (2020-2025)
9.5.2 Europe Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Neurodegenerative Drugs Production (2020-2025)
9.6.1 Japan Neurodegenerative Drugs Production Growth Rate (2020-2025)
9.6.2 Japan Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Neurodegenerative Drugs Production (2020-2025)
9.7.1 China Neurodegenerative Drugs Production Growth Rate (2020-2025)
9.7.2 China Neurodegenerative Drugs Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Novartis
10.1.1 Novartis Basic Information
10.1.2 Novartis Neurodegenerative Drugs Product Overview
10.1.3 Novartis Neurodegenerative Drugs Product Market Performance
10.1.4 Novartis Business Overview
10.1.5 Novartis SWOT Analysis
10.1.6 Novartis Recent Developments
10.2 Pfizer
10.2.1 Pfizer Basic Information
10.2.2 Pfizer Neurodegenerative Drugs Product Overview
10.2.3 Pfizer Neurodegenerative Drugs Product Market Performance
10.2.4 Pfizer Business Overview
10.2.5 Pfizer SWOT Analysis
10.2.6 Pfizer Recent Developments
10.3 Merck Serono
10.3.1 Merck Serono Basic Information
10.3.2 Merck Serono Neurodegenerative Drugs Product Overview
10.3.3 Merck Serono Neurodegenerative Drugs Product Market Performance
10.3.4 Merck Serono Business Overview
10.3.5 Merck Serono SWOT Analysis
10.3.6 Merck Serono Recent Developments
10.4 Biogen Idec
10.4.1 Biogen Idec Basic Information
10.4.2 Biogen Idec Neurodegenerative Drugs Product Overview
10.4.3 Biogen Idec Neurodegenerative Drugs Product Market Performance
10.4.4 Biogen Idec Business Overview
10.4.5 Biogen Idec Recent Developments
10.5 TEVA
10.5.1 TEVA Basic Information
10.5.2 TEVA Neurodegenerative Drugs Product Overview
10.5.3 TEVA Neurodegenerative Drugs Product Market Performance
10.5.4 TEVA Business Overview
10.5.5 TEVA Recent Developments
10.6 UCB
10.6.1 UCB Basic Information
10.6.2 UCB Neurodegenerative Drugs Product Overview
10.6.3 UCB Neurodegenerative Drugs Product Market Performance
10.6.4 UCB Business Overview
10.6.5 UCB Recent Developments
10.7 Boehringer Ingelheim
10.7.1 Boehringer Ingelheim Basic Information
10.7.2 Boehringer Ingelheim Neurodegenerative Drugs Product Overview
10.7.3 Boehringer Ingelheim Neurodegenerative Drugs Product Market Performance
10.7.4 Boehringer Ingelheim Business Overview
10.7.5 Boehringer Ingelheim Recent Developments
10.8 Sanofi
10.8.1 Sanofi Basic Information
10.8.2 Sanofi Neurodegenerative Drugs Product Overview
10.8.3 Sanofi Neurodegenerative Drugs Product Market Performance
10.8.4 Sanofi Business Overview
10.8.5 Sanofi Recent Developments
10.9 GlaxoSmithKline
10.9.1 GlaxoSmithKline Basic Information
10.9.2 GlaxoSmithKline Neurodegenerative Drugs Product Overview
10.9.3 GlaxoSmithKline Neurodegenerative Drugs Product Market Performance
10.9.4 GlaxoSmithKline Business Overview
10.9.5 GlaxoSmithKline Recent Developments
10.10 Livzon Pharmaceutical
10.10.1 Livzon Pharmaceutical Basic Information
10.10.2 Livzon Pharmaceutical Neurodegenerative Drugs Product Overview
10.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.10.4 Livzon Pharmaceutical Business Overview
10.10.5 Livzon Pharmaceutical Recent Developments
10.11 Haisco Pharmaceutical
10.11.1 Haisco Pharmaceutical Basic Information
10.11.2 Haisco Pharmaceutical Neurodegenerative Drugs Product Overview
10.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.11.4 Haisco Pharmaceutical Business Overview
10.11.5 Haisco Pharmaceutical Recent Developments
10.12 Jingxin Pharmaceutical
10.12.1 Jingxin Pharmaceutical Basic Information
10.12.2 Jingxin Pharmaceutical Neurodegenerative Drugs Product Overview
10.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.12.4 Jingxin Pharmaceutical Business Overview
10.12.5 Jingxin Pharmaceutical Recent Developments
10.13 Dongcheng Biochemicals
10.13.1 Dongcheng Biochemicals Basic Information
10.13.2 Dongcheng Biochemicals Neurodegenerative Drugs Product Overview
10.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Product Market Performance
10.13.4 Dongcheng Biochemicals Business Overview
10.13.5 Dongcheng Biochemicals Recent Developments
10.14 Hisun Pharmaceutical
10.14.1 Hisun Pharmaceutical Basic Information
10.14.2 Hisun Pharmaceutical Neurodegenerative Drugs Product Overview
10.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.14.4 Hisun Pharmaceutical Business Overview
10.14.5 Hisun Pharmaceutical Recent Developments
10.15 Luye Pharma
10.15.1 Luye Pharma Basic Information
10.15.2 Luye Pharma Neurodegenerative Drugs Product Overview
10.15.3 Luye Pharma Neurodegenerative Drugs Product Market Performance
10.15.4 Luye Pharma Business Overview
10.15.5 Luye Pharma Recent Developments
10.16 Ark Pharmaceutical
10.16.1 Ark Pharmaceutical Basic Information
10.16.2 Ark Pharmaceutical Neurodegenerative Drugs Product Overview
10.16.3 Ark Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.16.4 Ark Pharmaceutical Business Overview
10.16.5 Ark Pharmaceutical Recent Developments
10.17 Kanghong Pharmaceutical
10.17.1 Kanghong Pharmaceutical Basic Information
10.17.2 Kanghong Pharmaceutical Neurodegenerative Drugs Product Overview
10.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.17.4 Kanghong Pharmaceutical Business Overview
10.17.5 Kanghong Pharmaceutical Recent Developments
10.18 Huahai Pharmaceutical
10.18.1 Huahai Pharmaceutical Basic Information
10.18.2 Huahai Pharmaceutical Neurodegenerative Drugs Product Overview
10.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Product Market Performance
10.18.4 Huahai Pharmaceutical Business Overview
10.18.5 Huahai Pharmaceutical Recent Developments
10.19 BORA PHARMACEUTICALS
10.19.1 BORA PHARMACEUTICALS Basic Information
10.19.2 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Overview
10.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Market Performance
10.19.4 BORA PHARMACEUTICALS Business Overview
10.19.5 BORA PHARMACEUTICALS Recent Developments
11 NEURODEGENERATIVE DRUGS MARKET FORECAST BY REGION
11.1 Global Neurodegenerative Drugs Market Size Forecast
11.2 Global Neurodegenerative Drugs Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neurodegenerative Drugs Market Size Forecast by Country
11.2.3 Asia Pacific Neurodegenerative Drugs Market Size Forecast by Region
11.2.4 South America Neurodegenerative Drugs Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Neurodegenerative Drugs by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)
12.1 Global Neurodegenerative Drugs Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Neurodegenerative Drugs by Type (2026-2033)
12.1.2 Global Neurodegenerative Drugs Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Neurodegenerative Drugs by Type (2026-2033)
12.2 Global Neurodegenerative Drugs Market Forecast by Application (2026-2033)
12.2.1 Global Neurodegenerative Drugs Sales (K MT) Forecast by Application
12.2.2 Global Neurodegenerative Drugs Market Size (M USD) Forecast by Application (2026-2033)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Neurodegenerative Drugs Market Size Comparison by Region (M USD)
Table 5. Global Neurodegenerative Drugs Sales (K MT) by Manufacturers (2020-2025)
Table 6. Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Neurodegenerative Drugs Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Neurodegenerative Drugs Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Drugs as of 2024)
Table 10. Global Market Neurodegenerative Drugs Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Neurodegenerative Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Neurodegenerative Drugs Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Neurodegenerative Drugs Sales by Type (K MT)
Table 26. Global Neurodegenerative Drugs Market Size by Type (M USD)
Table 27. Global Neurodegenerative Drugs Sales (K MT) by Type (2020-2025)
Table 28. Global Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
Table 29. Global Neurodegenerative Drugs Market Size (M USD) by Type (2020-2025)
Table 30. Global Neurodegenerative Drugs Market Size Share by Type (2020-2025)
Table 31. Global Neurodegenerative Drugs Price (USD/KG) by Type (2020-2025)
Table 32. Global Neurodegenerative Drugs Sales (K MT) by Application
Table 33. Global Neurodegenerative Drugs Market Size by Application
Table 34. Global Neurodegenerative Drugs Sales by Application (2020-2025) & (K MT)
Table 35. Global Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
Table 36. Global Neurodegenerative Drugs Market Size by Application (2020-2025) & (M USD)
Table 37. Global Neurodegenerative Drugs Market Share by Application (2020-2025)
Table 38. Global Neurodegenerative Drugs Sales Growth Rate by Application (2020-2025)
Table 39. Global Neurodegenerative Drugs Sales by Region (2020-2025) & (K MT)
Table 40. Global Neurodegenerative Drugs Sales Market Share by Region (2020-2025)
Table 41. Global Neurodegenerative Drugs Market Size by Region (2020-2025) & (M USD)
Table 42. Global Neurodegenerative Drugs Market Size Market Share by Region (2020-2025)
Table 43. North America Neurodegenerative Drugs Sales by Country (2020-2025) & (K MT)
Table 44. North America Neurodegenerative Drugs Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Neurodegenerative Drugs Sales by Country (2020-2025) & (K MT)
Table 46. Europe Neurodegenerative Drugs Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Neurodegenerative Drugs Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Neurodegenerative Drugs Market Size by Region (2020-2025) & (M USD)
Table 49. South America Neurodegenerative Drugs Sales by Country (2020-2025) & (K MT)
Table 50. South America Neurodegenerative Drugs Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Neurodegenerative Drugs Sales by Region (2020-2025) & (K MT)
Table 52. Middle East and Africa Neurodegenerative Drugs Market Size by Region (2020-2025) & (M USD)
Table 53. Global Neurodegenerative Drugs Production (K MT) by Region(2020-2025)
Table 54. Global Neurodegenerative Drugs Revenue (US$ Million) by Region (2020-2025)
Table 55. Global Neurodegenerative Drugs Revenue Market Share by Region (2020-2025)
Table 56. Global Neurodegenerative Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 57. North America Neurodegenerative Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. Europe Neurodegenerative Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Japan Neurodegenerative Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. China Neurodegenerative Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. Novartis Basic Information
Table 62. Novartis Neurodegenerative Drugs Product Overview
Table 63. Novartis Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 64. Novartis Business Overview
Table 65. Novartis SWOT Analysis
Table 66. Novartis Recent Developments
Table 67. Pfizer Basic Information
Table 68. Pfizer Neurodegenerative Drugs Product Overview
Table 69. Pfizer Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 70. Pfizer Business Overview
Table 71. Pfizer SWOT Analysis
Table 72. Pfizer Recent Developments
Table 73. Merck Serono Basic Information
Table 74. Merck Serono Neurodegenerative Drugs Product Overview
Table 75. Merck Serono Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 76. Merck Serono Business Overview
Table 77. Merck Serono SWOT Analysis
Table 78. Merck Serono Recent Developments
Table 79. Biogen Idec Basic Information
Table 80. Biogen Idec Neurodegenerative Drugs Product Overview
Table 81. Biogen Idec Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 82. Biogen Idec Business Overview
Table 83. Biogen Idec Recent Developments
Table 84. TEVA Basic Information
Table 85. TEVA Neurodegenerative Drugs Product Overview
Table 86. TEVA Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 87. TEVA Business Overview
Table 88. TEVA Recent Developments
Table 89. UCB Basic Information
Table 90. UCB Neurodegenerative Drugs Product Overview
Table 91. UCB Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 92. UCB Business Overview
Table 93. UCB Recent Developments
Table 94. Boehringer Ingelheim Basic Information
Table 95. Boehringer Ingelheim Neurodegenerative Drugs Product Overview
Table 96. Boehringer Ingelheim Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 97. Boehringer Ingelheim Business Overview
Table 98. Boehringer Ingelheim Recent Developments
Table 99. Sanofi Basic Information
Table 100. Sanofi Neurodegenerative Drugs Product Overview
Table 101. Sanofi Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 102. Sanofi Business Overview
Table 103. Sanofi Recent Developments
Table 104. GlaxoSmithKline Basic Information
Table 105. GlaxoSmithKline Neurodegenerative Drugs Product Overview
Table 106. GlaxoSmithKline Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 107. GlaxoSmithKline Business Overview
Table 108. GlaxoSmithKline Recent Developments
Table 109. Livzon Pharmaceutical Basic Information
Table 110. Livzon Pharmaceutical Neurodegenerative Drugs Product Overview
Table 111. Livzon Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 112. Livzon Pharmaceutical Business Overview
Table 113. Livzon Pharmaceutical Recent Developments
Table 114. Haisco Pharmaceutical Basic Information
Table 115. Haisco Pharmaceutical Neurodegenerative Drugs Product Overview
Table 116. Haisco Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 117. Haisco Pharmaceutical Business Overview
Table 118. Haisco Pharmaceutical Recent Developments
Table 119. Jingxin Pharmaceutical Basic Information
Table 120. Jingxin Pharmaceutical Neurodegenerative Drugs Product Overview
Table 121. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 122. Jingxin Pharmaceutical Business Overview
Table 123. Jingxin Pharmaceutical Recent Developments
Table 124. Dongcheng Biochemicals Basic Information
Table 125. Dongcheng Biochemicals Neurodegenerative Drugs Product Overview
Table 126. Dongcheng Biochemicals Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 127. Dongcheng Biochemicals Business Overview
Table 128. Dongcheng Biochemicals Recent Developments
Table 129. Hisun Pharmaceutical Basic Information
Table 130. Hisun Pharmaceutical Neurodegenerative Drugs Product Overview
Table 131. Hisun Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 132. Hisun Pharmaceutical Business Overview
Table 133. Hisun Pharmaceutical Recent Developments
Table 134. Luye Pharma Basic Information
Table 135. Luye Pharma Neurodegenerative Drugs Product Overview
Table 136. Luye Pharma Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 137. Luye Pharma Business Overview
Table 138. Luye Pharma Recent Developments
Table 139. Ark Pharmaceutical Basic Information
Table 140. Ark Pharmaceutical Neurodegenerative Drugs Product Overview
Table 141. Ark Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 142. Ark Pharmaceutical Business Overview
Table 143. Ark Pharmaceutical Recent Developments
Table 144. Kanghong Pharmaceutical Basic Information
Table 145. Kanghong Pharmaceutical Neurodegenerative Drugs Product Overview
Table 146. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 147. Kanghong Pharmaceutical Business Overview
Table 148. Kanghong Pharmaceutical Recent Developments
Table 149. Huahai Pharmaceutical Basic Information
Table 150. Huahai Pharmaceutical Neurodegenerative Drugs Product Overview
Table 151. Huahai Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 152. Huahai Pharmaceutical Business Overview
Table 153. Huahai Pharmaceutical Recent Developments
Table 154. BORA PHARMACEUTICALS Basic Information
Table 155. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Overview
Table 156. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 157. BORA PHARMACEUTICALS Business Overview
Table 158. BORA PHARMACEUTICALS Recent Developments
Table 159. Global Neurodegenerative Drugs Sales Forecast by Region (2026-2033) & (K MT)
Table 160. Global Neurodegenerative Drugs Market Size Forecast by Region (2026-2033) & (M USD)
Table 161. North America Neurodegenerative Drugs Sales Forecast by Country (2026-2033) & (K MT)
Table 162. North America Neurodegenerative Drugs Market Size Forecast by Country (2026-2033) & (M USD)
Table 163. Europe Neurodegenerative Drugs Sales Forecast by Country (2026-2033) & (K MT)
Table 164. Europe Neurodegenerative Drugs Market Size Forecast by Country (2026-2033) & (M USD)
Table 165. Asia Pacific Neurodegenerative Drugs Sales Forecast by Region (2026-2033) & (K MT)
Table 166. Asia Pacific Neurodegenerative Drugs Market Size Forecast by Region (2026-2033) & (M USD)
Table 167. South America Neurodegenerative Drugs Sales Forecast by Country (2026-2033) & (K MT)
Table 168. South America Neurodegenerative Drugs Market Size Forecast by Country (2026-2033) & (M USD)
Table 169. Middle East and Africa Neurodegenerative Drugs Sales Forecast by Country (2026-2033) & (Units)
Table 170. Middle East and Africa Neurodegenerative Drugs Market Size Forecast by Country (2026-2033) & (M USD)
Table 171. Global Neurodegenerative Drugs Sales Forecast by Type (2026-2033) & (K MT)
Table 172. Global Neurodegenerative Drugs Market Size Forecast by Type (2026-2033) & (M USD)
Table 173. Global Neurodegenerative Drugs Price Forecast by Type (2026-2033) & (USD/KG)
Table 174. Global Neurodegenerative Drugs Sales (K MT) Forecast by Application (2026-2033)
Table 175. Global Neurodegenerative Drugs Market Size Forecast by Application (2026-2033) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Neurodegenerative Drugs Market Size Comparison by Region (M USD)
Table 5. Global Neurodegenerative Drugs Sales (K MT) by Manufacturers (2020-2025)
Table 6. Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Neurodegenerative Drugs Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Neurodegenerative Drugs Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Drugs as of 2024)
Table 10. Global Market Neurodegenerative Drugs Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Neurodegenerative Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Neurodegenerative Drugs Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Neurodegenerative Drugs Sales by Type (K MT)
Table 26. Global Neurodegenerative Drugs Market Size by Type (M USD)
Table 27. Global Neurodegenerative Drugs Sales (K MT) by Type (2020-2025)
Table 28. Global Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
Table 29. Global Neurodegenerative Drugs Market Size (M USD) by Type (2020-2025)
Table 30. Global Neurodegenerative Drugs Market Size Share by Type (2020-2025)
Table 31. Global Neurodegenerative Drugs Price (USD/KG) by Type (2020-2025)
Table 32. Global Neurodegenerative Drugs Sales (K MT) by Application
Table 33. Global Neurodegenerative Drugs Market Size by Application
Table 34. Global Neurodegenerative Drugs Sales by Application (2020-2025) & (K MT)
Table 35. Global Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
Table 36. Global Neurodegenerative Drugs Market Size by Application (2020-2025) & (M USD)
Table 37. Global Neurodegenerative Drugs Market Share by Application (2020-2025)
Table 38. Global Neurodegenerative Drugs Sales Growth Rate by Application (2020-2025)
Table 39. Global Neurodegenerative Drugs Sales by Region (2020-2025) & (K MT)
Table 40. Global Neurodegenerative Drugs Sales Market Share by Region (2020-2025)
Table 41. Global Neurodegenerative Drugs Market Size by Region (2020-2025) & (M USD)
Table 42. Global Neurodegenerative Drugs Market Size Market Share by Region (2020-2025)
Table 43. North America Neurodegenerative Drugs Sales by Country (2020-2025) & (K MT)
Table 44. North America Neurodegenerative Drugs Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Neurodegenerative Drugs Sales by Country (2020-2025) & (K MT)
Table 46. Europe Neurodegenerative Drugs Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Neurodegenerative Drugs Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Neurodegenerative Drugs Market Size by Region (2020-2025) & (M USD)
Table 49. South America Neurodegenerative Drugs Sales by Country (2020-2025) & (K MT)
Table 50. South America Neurodegenerative Drugs Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Neurodegenerative Drugs Sales by Region (2020-2025) & (K MT)
Table 52. Middle East and Africa Neurodegenerative Drugs Market Size by Region (2020-2025) & (M USD)
Table 53. Global Neurodegenerative Drugs Production (K MT) by Region(2020-2025)
Table 54. Global Neurodegenerative Drugs Revenue (US$ Million) by Region (2020-2025)
Table 55. Global Neurodegenerative Drugs Revenue Market Share by Region (2020-2025)
Table 56. Global Neurodegenerative Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 57. North America Neurodegenerative Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. Europe Neurodegenerative Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Japan Neurodegenerative Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. China Neurodegenerative Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. Novartis Basic Information
Table 62. Novartis Neurodegenerative Drugs Product Overview
Table 63. Novartis Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 64. Novartis Business Overview
Table 65. Novartis SWOT Analysis
Table 66. Novartis Recent Developments
Table 67. Pfizer Basic Information
Table 68. Pfizer Neurodegenerative Drugs Product Overview
Table 69. Pfizer Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 70. Pfizer Business Overview
Table 71. Pfizer SWOT Analysis
Table 72. Pfizer Recent Developments
Table 73. Merck Serono Basic Information
Table 74. Merck Serono Neurodegenerative Drugs Product Overview
Table 75. Merck Serono Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 76. Merck Serono Business Overview
Table 77. Merck Serono SWOT Analysis
Table 78. Merck Serono Recent Developments
Table 79. Biogen Idec Basic Information
Table 80. Biogen Idec Neurodegenerative Drugs Product Overview
Table 81. Biogen Idec Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 82. Biogen Idec Business Overview
Table 83. Biogen Idec Recent Developments
Table 84. TEVA Basic Information
Table 85. TEVA Neurodegenerative Drugs Product Overview
Table 86. TEVA Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 87. TEVA Business Overview
Table 88. TEVA Recent Developments
Table 89. UCB Basic Information
Table 90. UCB Neurodegenerative Drugs Product Overview
Table 91. UCB Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 92. UCB Business Overview
Table 93. UCB Recent Developments
Table 94. Boehringer Ingelheim Basic Information
Table 95. Boehringer Ingelheim Neurodegenerative Drugs Product Overview
Table 96. Boehringer Ingelheim Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 97. Boehringer Ingelheim Business Overview
Table 98. Boehringer Ingelheim Recent Developments
Table 99. Sanofi Basic Information
Table 100. Sanofi Neurodegenerative Drugs Product Overview
Table 101. Sanofi Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 102. Sanofi Business Overview
Table 103. Sanofi Recent Developments
Table 104. GlaxoSmithKline Basic Information
Table 105. GlaxoSmithKline Neurodegenerative Drugs Product Overview
Table 106. GlaxoSmithKline Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 107. GlaxoSmithKline Business Overview
Table 108. GlaxoSmithKline Recent Developments
Table 109. Livzon Pharmaceutical Basic Information
Table 110. Livzon Pharmaceutical Neurodegenerative Drugs Product Overview
Table 111. Livzon Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 112. Livzon Pharmaceutical Business Overview
Table 113. Livzon Pharmaceutical Recent Developments
Table 114. Haisco Pharmaceutical Basic Information
Table 115. Haisco Pharmaceutical Neurodegenerative Drugs Product Overview
Table 116. Haisco Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 117. Haisco Pharmaceutical Business Overview
Table 118. Haisco Pharmaceutical Recent Developments
Table 119. Jingxin Pharmaceutical Basic Information
Table 120. Jingxin Pharmaceutical Neurodegenerative Drugs Product Overview
Table 121. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 122. Jingxin Pharmaceutical Business Overview
Table 123. Jingxin Pharmaceutical Recent Developments
Table 124. Dongcheng Biochemicals Basic Information
Table 125. Dongcheng Biochemicals Neurodegenerative Drugs Product Overview
Table 126. Dongcheng Biochemicals Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 127. Dongcheng Biochemicals Business Overview
Table 128. Dongcheng Biochemicals Recent Developments
Table 129. Hisun Pharmaceutical Basic Information
Table 130. Hisun Pharmaceutical Neurodegenerative Drugs Product Overview
Table 131. Hisun Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 132. Hisun Pharmaceutical Business Overview
Table 133. Hisun Pharmaceutical Recent Developments
Table 134. Luye Pharma Basic Information
Table 135. Luye Pharma Neurodegenerative Drugs Product Overview
Table 136. Luye Pharma Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 137. Luye Pharma Business Overview
Table 138. Luye Pharma Recent Developments
Table 139. Ark Pharmaceutical Basic Information
Table 140. Ark Pharmaceutical Neurodegenerative Drugs Product Overview
Table 141. Ark Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 142. Ark Pharmaceutical Business Overview
Table 143. Ark Pharmaceutical Recent Developments
Table 144. Kanghong Pharmaceutical Basic Information
Table 145. Kanghong Pharmaceutical Neurodegenerative Drugs Product Overview
Table 146. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 147. Kanghong Pharmaceutical Business Overview
Table 148. Kanghong Pharmaceutical Recent Developments
Table 149. Huahai Pharmaceutical Basic Information
Table 150. Huahai Pharmaceutical Neurodegenerative Drugs Product Overview
Table 151. Huahai Pharmaceutical Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 152. Huahai Pharmaceutical Business Overview
Table 153. Huahai Pharmaceutical Recent Developments
Table 154. BORA PHARMACEUTICALS Basic Information
Table 155. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Overview
Table 156. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 157. BORA PHARMACEUTICALS Business Overview
Table 158. BORA PHARMACEUTICALS Recent Developments
Table 159. Global Neurodegenerative Drugs Sales Forecast by Region (2026-2033) & (K MT)
Table 160. Global Neurodegenerative Drugs Market Size Forecast by Region (2026-2033) & (M USD)
Table 161. North America Neurodegenerative Drugs Sales Forecast by Country (2026-2033) & (K MT)
Table 162. North America Neurodegenerative Drugs Market Size Forecast by Country (2026-2033) & (M USD)
Table 163. Europe Neurodegenerative Drugs Sales Forecast by Country (2026-2033) & (K MT)
Table 164. Europe Neurodegenerative Drugs Market Size Forecast by Country (2026-2033) & (M USD)
Table 165. Asia Pacific Neurodegenerative Drugs Sales Forecast by Region (2026-2033) & (K MT)
Table 166. Asia Pacific Neurodegenerative Drugs Market Size Forecast by Region (2026-2033) & (M USD)
Table 167. South America Neurodegenerative Drugs Sales Forecast by Country (2026-2033) & (K MT)
Table 168. South America Neurodegenerative Drugs Market Size Forecast by Country (2026-2033) & (M USD)
Table 169. Middle East and Africa Neurodegenerative Drugs Sales Forecast by Country (2026-2033) & (Units)
Table 170. Middle East and Africa Neurodegenerative Drugs Market Size Forecast by Country (2026-2033) & (M USD)
Table 171. Global Neurodegenerative Drugs Sales Forecast by Type (2026-2033) & (K MT)
Table 172. Global Neurodegenerative Drugs Market Size Forecast by Type (2026-2033) & (M USD)
Table 173. Global Neurodegenerative Drugs Price Forecast by Type (2026-2033) & (USD/KG)
Table 174. Global Neurodegenerative Drugs Sales (K MT) Forecast by Application (2026-2033)
Table 175. Global Neurodegenerative Drugs Market Size Forecast by Application (2026-2033) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Neurodegenerative Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neurodegenerative Drugs Market Size (M USD), 2024-2033
Figure 5. Global Neurodegenerative Drugs Market Size (M USD) (2020-2033)
Figure 6. Global Neurodegenerative Drugs Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neurodegenerative Drugs Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Neurodegenerative Drugs Product Life Cycle
Figure 13. Neurodegenerative Drugs Sales Share by Manufacturers in 2024
Figure 14. Global Neurodegenerative Drugs Revenue Share by Manufacturers in 2024
Figure 15. Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Neurodegenerative Drugs Average Price (USD/KG) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Neurodegenerative Drugs Revenue in 2024
Figure 18. Industry Chain Map of Neurodegenerative Drugs
Figure 19. Global Neurodegenerative Drugs Market PEST Analysis
Figure 20. Global Neurodegenerative Drugs Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Neurodegenerative Drugs Market Share by Type
Figure 27. Sales Market Share of Neurodegenerative Drugs by Type (2020-2025)
Figure 28. Sales Market Share of Neurodegenerative Drugs by Type in 2024
Figure 29. Market Size Share of Neurodegenerative Drugs by Type (2020-2025)
Figure 30. Market Size Share of Neurodegenerative Drugs by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Neurodegenerative Drugs Market Share by Application
Figure 33. Global Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
Figure 34. Global Neurodegenerative Drugs Sales Market Share by Application in 2024
Figure 35. Global Neurodegenerative Drugs Market Share by Application (2020-2025)
Figure 36. Global Neurodegenerative Drugs Market Share by Application in 2024
Figure 37. Global Neurodegenerative Drugs Sales Growth Rate by Application (2020-2025)
Figure 38. Global Neurodegenerative Drugs Sales Market Share by Region (2020-2025)
Figure 39. Global Neurodegenerative Drugs Market Size Market Share by Region (2020-2025)
Figure 40. North America Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Neurodegenerative Drugs Sales Market Share by Country in 2024
Figure 43. North America Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Neurodegenerative Drugs Market Size Market Share by Country in 2024
Figure 45. U.S. Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Neurodegenerative Drugs Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Neurodegenerative Drugs Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Neurodegenerative Drugs Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Neurodegenerative Drugs Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Neurodegenerative Drugs Sales Market Share by Country in 2024
Figure 53. Europe Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Neurodegenerative Drugs Market Size Market Share by Country in 2024
Figure 55. Germany Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Neurodegenerative Drugs Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Neurodegenerative Drugs Sales Market Share by Region in 2024
Figure 67. Asia Pacific Neurodegenerative Drugs Market Size Market Share by Region in 2024
Figure 68. China Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Neurodegenerative Drugs Sales and Growth Rate (K MT)
Figure 79. South America Neurodegenerative Drugs Sales Market Share by Country in 2024
Figure 80. South America Neurodegenerative Drugs Market Size and Growth Rate (M USD)
Figure 81. South America Neurodegenerative Drugs Market Size Market Share by Country in 2024
Figure 82. Brazil Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Neurodegenerative Drugs Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Neurodegenerative Drugs Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Neurodegenerative Drugs Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Neurodegenerative Drugs Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Neurodegenerative Drugs Production Market Share by Region (2020-2025)
Figure 103. North America Neurodegenerative Drugs Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Neurodegenerative Drugs Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Neurodegenerative Drugs Production (K MT) Growth Rate (2020-2025)
Figure 106. China Neurodegenerative Drugs Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Neurodegenerative Drugs Sales Forecast by Volume (2020-2033) & (K MT)
Figure 108. Global Neurodegenerative Drugs Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Neurodegenerative Drugs Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Neurodegenerative Drugs Market Share Forecast by Type (2026-2033)
Figure 111. Global Neurodegenerative Drugs Sales Forecast by Application (2026-2033)
Figure 112. Global Neurodegenerative Drugs Market Share Forecast by Application (2026-2033)
Figure 1. Product Picture of Neurodegenerative Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neurodegenerative Drugs Market Size (M USD), 2024-2033
Figure 5. Global Neurodegenerative Drugs Market Size (M USD) (2020-2033)
Figure 6. Global Neurodegenerative Drugs Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neurodegenerative Drugs Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Neurodegenerative Drugs Product Life Cycle
Figure 13. Neurodegenerative Drugs Sales Share by Manufacturers in 2024
Figure 14. Global Neurodegenerative Drugs Revenue Share by Manufacturers in 2024
Figure 15. Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Neurodegenerative Drugs Average Price (USD/KG) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Neurodegenerative Drugs Revenue in 2024
Figure 18. Industry Chain Map of Neurodegenerative Drugs
Figure 19. Global Neurodegenerative Drugs Market PEST Analysis
Figure 20. Global Neurodegenerative Drugs Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Neurodegenerative Drugs Market Share by Type
Figure 27. Sales Market Share of Neurodegenerative Drugs by Type (2020-2025)
Figure 28. Sales Market Share of Neurodegenerative Drugs by Type in 2024
Figure 29. Market Size Share of Neurodegenerative Drugs by Type (2020-2025)
Figure 30. Market Size Share of Neurodegenerative Drugs by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Neurodegenerative Drugs Market Share by Application
Figure 33. Global Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
Figure 34. Global Neurodegenerative Drugs Sales Market Share by Application in 2024
Figure 35. Global Neurodegenerative Drugs Market Share by Application (2020-2025)
Figure 36. Global Neurodegenerative Drugs Market Share by Application in 2024
Figure 37. Global Neurodegenerative Drugs Sales Growth Rate by Application (2020-2025)
Figure 38. Global Neurodegenerative Drugs Sales Market Share by Region (2020-2025)
Figure 39. Global Neurodegenerative Drugs Market Size Market Share by Region (2020-2025)
Figure 40. North America Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Neurodegenerative Drugs Sales Market Share by Country in 2024
Figure 43. North America Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Neurodegenerative Drugs Market Size Market Share by Country in 2024
Figure 45. U.S. Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Neurodegenerative Drugs Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Neurodegenerative Drugs Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Neurodegenerative Drugs Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Neurodegenerative Drugs Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Neurodegenerative Drugs Sales Market Share by Country in 2024
Figure 53. Europe Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Neurodegenerative Drugs Market Size Market Share by Country in 2024
Figure 55. Germany Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Neurodegenerative Drugs Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Neurodegenerative Drugs Sales Market Share by Region in 2024
Figure 67. Asia Pacific Neurodegenerative Drugs Market Size Market Share by Region in 2024
Figure 68. China Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Neurodegenerative Drugs Sales and Growth Rate (K MT)
Figure 79. South America Neurodegenerative Drugs Sales Market Share by Country in 2024
Figure 80. South America Neurodegenerative Drugs Market Size and Growth Rate (M USD)
Figure 81. South America Neurodegenerative Drugs Market Size Market Share by Country in 2024
Figure 82. Brazil Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Neurodegenerative Drugs Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Neurodegenerative Drugs Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Neurodegenerative Drugs Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Neurodegenerative Drugs Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Neurodegenerative Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Neurodegenerative Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Neurodegenerative Drugs Production Market Share by Region (2020-2025)
Figure 103. North America Neurodegenerative Drugs Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Neurodegenerative Drugs Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Neurodegenerative Drugs Production (K MT) Growth Rate (2020-2025)
Figure 106. China Neurodegenerative Drugs Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Neurodegenerative Drugs Sales Forecast by Volume (2020-2033) & (K MT)
Figure 108. Global Neurodegenerative Drugs Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Neurodegenerative Drugs Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Neurodegenerative Drugs Market Share Forecast by Type (2026-2033)
Figure 111. Global Neurodegenerative Drugs Sales Forecast by Application (2026-2033)
Figure 112. Global Neurodegenerative Drugs Market Share Forecast by Application (2026-2033)
